Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc, a London-listed early phase contract research organisation, focuses on human challenge trials and broader early-stage clinical services for infectious and respiratory diseases. The group complements its core UK facilities with German trial centres and consulting and biometry capabilities, providing end-to-end support from early development through later-stage outpatient studies.
The company has issued 1,386,991 new ordinary shares to three managers of Cryo-Store Limited as the first 50% equity tranche of the consideration for its previously announced acquisition of Cryostore. Following admission of these shares to AIM, hVIVO’s total shares in issue will rise to 688,401,079, modestly diluting existing holders while advancing the integration of Cryostore and aligning its management with the group’s long-term performance.
A further tranche of up to 1,386,991 new shares is scheduled to be issued on the second anniversary of the acquisition, contingent on the recipients remaining with the group. This staged, service-linked equity structure underpins retention of key Cryostore managers and signals hVIVO’s continued strategy of using targeted acquisitions and share-based consideration to strengthen its operational capabilities within the contract research market.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £7.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.
Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase contract research organisation specialising in human challenge clinical trials across infectious and respiratory diseases. The company operates the world’s largest quarantine facility in London, provides virology and immunology lab services under the hLAB brand, and serves a broad biopharma client base, including seven of the ten largest global players.
Through its German subsidiary CRS, hVIVO runs a 120-bed early-phase clinical trial network in Mannheim and Kiel, delivering first-in-human and proof-of-concept studies. Its Venn Life Sciences arm offers early drug development consulting and biometry services, while FluCamp and five clinical sites support integrated development from preclinical work through Phase II and III outpatient trials.
Average Trading Volume: 5,933,023
Technical Sentiment Signal: Sell
Current Market Cap: £67.33M
For a thorough assessment of HVO stock, go to TipRanks’ Stock Analysis page.